The FDA issued warning letters to 30 telehealth companies over false or misleading claims made about compounded GLP-1 products sold on their websites. It was the second wave of letters aimed at telehealth firms since the agency opened a broader campaign against misleading direct-to-consumer drug advertising in September 2025, and the largest single action against compounded GLP-1 marketing to that date. The conduct cited again centred on presenting compounded semaglutide and tirzepatide as equivalent to the FDA-approved products.
Sources: FDA press announcement
